Press release
Monopar to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
WILMETTE, Ill., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing
About this update from Monopar Therapeutics Inc.
WILMETTE, Ill. , Sept. 04, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that Chandler D. Robinson , MD, Monopar’s Chief Executive Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference . The Company’s presentation will be webcast beginning on Monday, September 9, 2024 at 7:00 a.m. ET . In person one-on-one meetings will take place at the Lotte New York Palace , NY, NY from September 9 - 11, 2024 . About Monopar Therapeutics Inc. Monopar Therapeutics is a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, including Phase 1-stage MNPR-101-Zr for imaging advanced cancers, Phase 1-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for the treatment of advanced cancers, as well as early development stage programs against solid cancers. For more information, visit: www.monopartx.com . CONTACT: Monopar Therapeutics Inc. Investor Relations Karthik Radhakrishnan Chief Financial Officer [email protected] Follow Monopar on social media for updates: Twitter: @MonoparTx LinkedIn: Monopar Therapeutics Source: Monopar Therapeutics Inc.
View stock analysis, news, and events for Monopar Therapeutics Inc.